RSCM
GPCR icon

Rock Springs Capital Management’s Structure Therapeutics GPCR Stock Holding History

Rock Springs Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4M Buy
640,317
+100
+0% +$4.42K 1.68% 14
2026
Q1 		$30.9M Sell
640,217
-108,019
-14% -$7.39M 1.82% 18
2025
Q4 		$52M Sell
748,236
-202,918
-21% -$8.29M 2.67% 10
2025
Q3 		$26.6M Sell
951,154
-184,725
-16% -$3.68M 1.56% 23
2025
Q2 		$23.6M Buy
1,135,879
+2,900
+0.3% +$63.8K 1.47% 27
2025
Q1 		$19.6M Buy
1,132,979
+52,016
+5% +$1.27M 1.12% 32
2024
Q4 		$29.3M Buy
1,080,963
+17,053
+2% +$605K 1.12% 33
2024
Q3 		$46.7M Buy
1,063,910
+64,048
+6% +$2.48M 1.52% 25
2024
Q2 		$39.3M Buy
999,862
+587,213
+142% +$24.1M 1.18% 34
2024
Q1 		$17.7M Buy
412,649
+125,973
+44% +$5.31M 0.45% 63
2023
Q4 		$11.7M Buy
+286,676
New +$16.4M 0.29% 68

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rock Springs Capital Management's GPCR Position: Q2 2026 in Review

Rock Springs Capital Management increased its Structure Therapeutics (GPCR) stake by 0.02% in Q2 2026, buying an estimated $4.42K and bringing the position to 640,317 shares worth $34.4M. The position accounts for 1.68% of the portfolio, ranked #14.

Rock Springs Capital Management first reported a position in GPCR in Q4 2023 and has held it in 11 quarters since. The position peaked at $52M in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Rock Springs Capital Management held 640,317 shares of Structure Therapeutics worth $34.4M as of Q2 2026.
  • Rock Springs Capital Management bought 100 Structure Therapeutics shares in Q2 2026, an estimated $4.42K.
  • Structure Therapeutics made up 1.68% of Rock Springs Capital Management's portfolio in Q2 2026, its #14 holding.
  • Rock Springs Capital Management first reported a position in Structure Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Rock Springs Capital Management's Structure Therapeutics position peaked at $52M in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.